PUBLISHER: The Business Research Company | PRODUCT CODE: 1706941
PUBLISHER: The Business Research Company | PRODUCT CODE: 1706941
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Global Market Report 2025
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs designed to manage type 2 diabetes by blocking the SGLT2 protein in the kidneys. This action prevents the reabsorption of glucose, leading to its excretion in the urine and helping to lower blood glucose levels. In addition to their role in controlling blood sugar, SGLT2 inhibitors can aid in weight loss and lower blood pressure, and they offer additional cardiovascular and renal benefits, which are valuable for managing diabetic complications.
The main types of SGLT2 inhibitors include Invokana, Jardiance, Farxiga (or Forxiga), and Suglat. Invokana is a prescription medication used to reduce blood sugar levels in adults with type 2 diabetes. These medications are generally administered orally and are utilized by various end users such as hospitals, homecare settings, and clinics.
The sodium glucose cotransporter 2 (SGLT 2) inhibitors market research report is one of a series of new reports from The Business Research Company that provides sodium glucose cotransporter 2 (SGLT 2) inhibitors market statistics, including the sodium glucose cotransporter 2 (SGLT 2) inhibitors industry's global market size, regional shares, competitors with a sodium glucose cotransporter 2 (SGLT 2) inhibitors market share, detailed sodium glucose cotransporter 2 (SGLT 2) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the sodium glucose cotransporter 2 (SGLT 2) inhibitors industry. This sodium glucose cotransporter 2 (SGLT 2) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The sodium glucose cotransporter 2 (SGLT2) inhibitors market size has grown strongly in recent years. It will grow from $10.17 billion in 2024 to $11.07 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to early clinical trial successes, rising regulatory approvals, increasing diabetes diagnosis rates, and the demand for innovative diabetes treatments.
The sodium glucose cotransporter 2 (SGLT2) inhibitors market size is expected to see strong growth in the next few years. It will grow to $15.4 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing obesity rates, growing awareness of diabetes management, and expanding applications in heart and kidney disease treatments. Major trends in the forecast period include the integration of combination therapies, personalized medicine approaches, technological improvement, and traditional drug development.
The rising prevalence of diabetes is expected to drive the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market. Diabetes refers to a group of metabolic conditions marked by high blood sugar levels due to defects in insulin secretion, insulin action, or both. The increase in diabetes cases can be attributed to factors such as urbanization, stress, environmental pollution, and limited access to healthcare services. SGLT2 inhibitors are used in diabetes treatment to lower blood glucose levels by preventing glucose reabsorption in the kidneys, leading to its excretion in urine. These inhibitors also provide cardiovascular and renal benefits, making them a key treatment option for managing diabetes and its complications. For example, in December 2023, the Australian Bureau of Statistics, a government agency, reported that in 2022, 5.3% of Australians, or around 1.3 million people, were diagnosed with diabetes. The rates were similar between males (5.8%) and females (4.9%). Diabetes prevalence has been rising steadily, particularly among older populations, with 18.7% of people aged 75 and older affected. Type 2 diabetes accounts for 87.6% of cases. Factors such as being born overseas, living in disadvantaged areas, and having a disability are linked to higher diabetes rates. Consequently, the increasing prevalence of diabetes is propelling the growth of the SGLT2 inhibitor market.
Leading companies in the SGLT2 inhibitor market are focusing on developing dual inhibitor therapies to enhance patient outcomes and blood sugar management. Dual inhibitor therapies target both sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2) to improve treatment efficacy for conditions such as heart failure and diabetes. For example, in May 2023, Lexicon Pharmaceuticals Inc., a U.S.-based biopharmaceutical firm, received FDA approval for sotagliflozin, a novel dual SGLT1 and SGLT2 inhibitor. This once-daily tablet is designed to reduce cardiovascular death, hospitalizations for heart failure, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Sotagliflozin helps by reducing renal glucose and sodium reabsorption, leading to decreased preload and afterload, as well as reduced sympathetic activity.
In December 2022, Torrent Pharmaceuticals, an India-based pharmaceutical company, formed a partnership with Boehringer Ingelheim International GmbH to co-market diabetes and cardiovascular disease treatments. This collaboration aims to develop solutions for glycemic control in adults with type 2 diabetes mellitus. Empagliflozin, a product of this partnership, not only reduces the risk of cardiovascular death in individuals with type 2 diabetes and cardiovascular disease but also lowers the risk of cardiovascular death and hospitalizations for heart failure in adults with heart failure. Boehringer Ingelheim International GmbH, a Germany-based pharmaceutical company, specializes in developing and manufacturing health products for humans and animals.
Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki pharmaceutical Co Ltd.
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The sodium glucose cotransporter 2 (SGLT2) inhibitors market consists of sales of luseogliflozin, remogliflozin, tofogliflozin and sergliflozin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on sodium glucose cotransporter 2 (sglt2) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for sodium glucose cotransporter 2 (sglt2) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sodium glucose cotransporter 2 (sglt2) inhibitors market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Invokana; Jardiance; Farxiga Or Forxiga; Suglat
- 2) By Route Of Administration: Oral Route; Other Route Of Administration
- 3) By End User: Hospitals; Homecare Settings; Clinics
- Subsegments:
- 1) By Invokana: Generic Invokana (Canagliflozin); Branded Invokana
- 2) By Jardiance: Generic Jardiance (Empagliflozin); Branded Jardiance
- 3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin); Branded Farxiga
- 4) By Suglat: Suglat (Sotagliflozin) For Diabetes; Suglat (Sotagliflozin) For Heart Failure
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson Inc.; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Characteristics
3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Trends And Strategies
4. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Growth Analysis And Strategic Analysis Framework
- 5.1. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Growth Rate Analysis
- 5.4. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Total Addressable Market (TAM)
6. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Segmentation
- 6.1. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Invokana
- Jardiance
- Farxiga Or Forxiga
- Suglat
- 6.2. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Route
- Other Route Of Administrations
- 6.3. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Homecare Settings
- Clinics
- 6.4. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Sub-Segmentation Of Invokana, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Generic Invokana (Canagliflozin)
- Branded Invokana
- 6.5. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Sub-Segmentation Of Jardiance, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Generic Jardiance (Empagliflozin)
- Branded Jardiance
- 6.6. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Sub-Segmentation Of Farxiga Or Forxiga, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Generic Farxiga (Dapagliflozin)
- Branded Farxiga
- 6.7. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Sub-Segmentation Of Suglat, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Suglat (Sotagliflozin) For Diabetes
- Suglat (Sotagliflozin) For Heart Failure
7. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Regional And Country Analysis
- 7.1. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 8.1. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 9.1. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
- 9.2. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 10.1. India Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 11.1. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
- 11.2. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 12.1. Australia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 13.1. Indonesia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 14.1. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
- 14.2. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 15.1. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
- 15.2. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 16.1. UK Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 17.1. Germany Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 18.1. France Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 19.1. Italy Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 20.1. Spain Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 21.1. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
- 21.2. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 22.1. Russia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 23.1. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
- 23.2. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 24.1. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
- 24.2. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 25.1. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
- 25.2. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 26.1. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
- 26.2. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 27.1. Brazil Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 28.1. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
- 28.2. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
- 29.1. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview
- 29.2. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Landscape And Company Profiles
- 30.1. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Landscape
- 30.2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
31. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Other Major And Innovative Companies
- 31.1. Bristol-Myers Squibb Company
- 31.2. AstraZeneca plc
- 31.3. Eli Lilly and Company
- 31.4. Boehringer Ingelheim International GmBH
- 31.5. Astellas Pharma Inc
- 31.6. Daiichi Sankyo Company Limited
- 31.7. Sun Pharmaceutical Industries Ltd
- 31.8. Sumitomo Dainippon Pharma Co. Ltd.
- 31.9. Taisho Pharmaceutical Holdings Co. Ltd.
- 31.10. Lupin Limited
- 31.11. Glenmark pharmaceuticals
- 31.12. Torrent Pharmaceuticals Ltd
- 31.13. Mankind Pharma Ltd
- 31.14. Kissei Pharmaceutical Co. Ltd.
- 31.15. Patsnap Synapse
32. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
34. Recent Developments In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market
35. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market High Potential Countries, Segments and Strategies
- 35.1 Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
